Summary: In this issue, Singh and colleagues describe a novel tumor-intrinsic mechanism of resistance to chimericantigen receptor (CAR) T-cell therapy targeting CD19 in B-cell malignancies. They show that reduced expression of death receptor genes in the tumors mediates resistance to killing by CAR T cells, leads to progressive CAR T-cell dysfunction, and is associated with unfavorable clinical outcome in patients. See related article by Singh et al., [p. 552][1] . [1]: /lookup/volpage/10/552?iss=4

中文翻译：

---

并非如此：抵抗死亡的肿瘤细胞驱动CAR T细胞功能障碍

摘要：在此问题中，Singh及其同事描述了针对B细胞恶性肿瘤中针对CD19的嵌合抗原受体（CAR）T细胞疗法耐药的新型肿瘤内在机制。他们表明，肿瘤中死亡受体基因表达的降低介导了对CAR T细胞杀伤的抗性，导致进行性CAR T细胞功能障碍，并与患者不良的临床预后相关。参见Singh等人的相关文章，[p。552] [1]。[1]：/ lookup / volpage / 10/552？iss = 4